Epinex’s International Patent Application for ACR (Albumin/Creatinine Ratio) Test published in Japan.
May 13, 2016
Epinex’s ACR ( First Ever Rapid Test for Chronic Kidney Disease Detection) Japanese Patent Application published.
The Epinex ACR Albumin/Creatinine Ratio Test* is the first quantitative rapid, lateral flow test that measures microalbuminuria, a marker for the early detection of kidney damage.
The Epinex ACR Test
The Epinex ACR Test is the first quantitative rapid, lateral flow test that measures microalbuminuria, a marker for the early detection of kidney damage. The Epinex ACR test is a unique new application of lateral flow technology, a well-accepted and proven technology. It is the second application (after the G1A test) of the company’s proprietary platform technology. No previous immunoassay in lateral flow format measures both albumin and creatinine.
The ACR test is frequently used on patients with chronic diseases such as diabetes and hypertension that are at an increased risk of developing kidney failure. Microalbuminuria in individuals with diabetes or hypertension has shown to be associated with increased risks of developing neuropathy, cardiovascular disease (CVD), retinopathy, preeclampsia, inflammatory conditions, and mortality.
* This product is under development, and is intended for information and evaluation process only. It is NOT APPROVED by the FDA.